Mark McClellan
Mark McClellan (Big Pharma/Lobbyist, health bureaucrat) | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Born | June 26, 1963 Austin, Texas, U.S. | ||||||||||||||||||||||||
Nationality | US | ||||||||||||||||||||||||
Alma mater | University of Texas at Austin, Harvard/Kennedy School, Massachusetts Institute of Technology | ||||||||||||||||||||||||
Parents | • Carole Keeton Strayhorn • Barr McClellan | ||||||||||||||||||||||||
Siblings | Scott McClellan | ||||||||||||||||||||||||
Member of | Covid Commission Planning Group | ||||||||||||||||||||||||
Party | Republican | ||||||||||||||||||||||||
Food and Drug Administration Commissioner who "streamlined" regulatory requirements for new drugs. Later made big bucks on boards of Big Pharma companies.
|
Mark Barr McClellan was commissioner of the United States Food and Drug Administration under President George W. Bush from 2002 through 2004, and subsequently as administrator of the Centers for Medicare and Medicaid Services from 2004 through 2006.[1][2][3] He was part of 2021 the Covid Commission Planning Group under Philip Zelikow.
Contents
Food and Drug Administration Commissioner
When Mark McClellan was named US Food and Drug Administration Commissioner, he was quickly confirmed by both political parties. In his first major speech to the "healthcare" industry in January 2003, McClellan set the tone for his tenure, stating, "Along with the new health policy initiatives in Congress, we need a lower-cost process for regulating new medical technologies — less costly, more rapid, and more predictable ways of determining that new drugs and other treatments meet FDA's high standards of safety and effectiveness." He stated he intended "streamlining regulatory requirements, clarifying guidance to industry, and meeting with companies early and often in the drug-approval process".[4]
Revolving door
In 2007, he was appointed as the chair of the Reagan-Udall Foundation, a public-private "partnership" between the U.S. Food and Drug Administration and Big Pharma.[5]
In 2013, Mark McClellan was given a position on the board of pharmaceutical giant Johnson & Johnson. In 2018, McClellan received $285,000 for sitting there, and had since taking the post been given $1 million in cash and stock awards.[6]
McClellan also receives compensation as a member of the advisory board of privately held Alignment Healthcare, which employs doctors and provides chronic-care management for Medicare Advantage plans in three states. Alignment Healthcare declined to disclose his compensation.[6]
He was appointed to Big Pharma corporation Cigna's board of directors in July 2018[7]. In 2019, life sciences and health data company Seer told that it had lured Mark McClellan on to its board. "Mark’s deep understanding of the health care ecosystem and visionary insights on policy reform will be crucial in informing our thinking as we work to bring our liquid biopsy and life sciences products to market," said Seer chief and founder Omid Farokhzad in a statement.[8]
He also had a position as Senior Fellow in Economic Studies at Brookings Institution from 2007[9].
Event Participated in
Event | Start | End | Location(s) | Description |
---|---|---|---|---|
WEF/Annual Meeting/2004 | 21 January 2004 | 25 January 2004 | Switzerland World Economic Forum | 2068 billionaires, CEOs and their politicians and "civil society" leaders met under the slogan Partnering for Prosperity and Security. "We have the people who matter," said World Economic Forum Co-Chief Executive Officer José María Figueres. |
References
- ↑ https://www.nytimes.com/2006/09/08/opinion/08fri3.html
- ↑ https://query.nytimes.com/gst/fullpage.html?res=9907E3D71F3BF936A2575AC0A9659C8B63
- ↑ https://query.nytimes.com/gst/fullpage.html?res=990DEFDC1E3DF932A15751C0A9629C8B63
- ↑ https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(03)14063-9.pdf
- ↑ https://reaganudall.org/about-us/board-directors
- ↑ a b https://kffhealthnews.org/news/health-policy-expert-and-former-fda-chief-mark-mcclellans-ties-to-pharma-draw-scrutiny/
- ↑ https://www.raps.org/News-and-Articles/News-Articles/2018/9/Revolving-Door-Between-Industry-and-FDA-Continues
- ↑ https://endpts.com/seer-entices-ex-fda-commissioner-mcclellan-to-its-board-vanda-tests-tradipitant-in-motion-sickness-study/
- ↑ https://www.brookings.edu/wp-content/uploads/2016/07/mcclellanm_cv.pdf